Calorie Fighter é desenvolvido como um suplemento para emagrecer ou controle de peso no tratamento e prevenção do sobrepeso e da obesidade, a fim de prevenir doenças relacionadas a esses tipos de problemas de saúde.
Um dispositivo médico são produtos usados para diagnosticar, prevenir, aliviar ou tratar doenças, deficiências ou lesões. Slim Boost + Calorie Fighter é aprovado pela CE, que verifica se o dispositivo está em conformidade com o padrão para dispositivos médicos e se a qualidade, segurança e desempenho do produto estão documentados.
Calorie Fighter é regulamentado pela Lægemiddelstyrelsen / Klasse IIb – e a prescrição não é necessária! SEMPRE leia atentamente o folheto antes de usar o produto.
– by KitoZyme (2015)
KiOnutrime-CsG® is a natural ingredient that is scientifically proven to help people to manage their weight. In a recently completed clinical trial1 it was found that overweight subjects consuming KiOnutrime-CsG® lost an average of 3.2kg over three months, compared with a small weight increase on average in the control group.
Produced by KitoZyme at its manufacturing facility in Belgium, KiOnutrime-CsG® works by safely preventing some of the fat in food from being absorbed by the body. It is a cationic (positively charged) biopolymer that binds with anionic (negatively charged) molecules such as fats and fatty acids and obstructs the emulsification and absorption of cholesterol.
Taken just a few minutes before a meal, KiOnutrime-CsG® will bind dietary fat in the stomach to form a gel that is later excreted naturally without being absorbed. A previous study carried out using a lab-based model of the human gut showed that KiOnutrime-CsG® can bind 42% of the fats ingested in a typical meal2 , as shown below in Figure 1. The latest human study, which is awaiting publication in a peer-reviewed journal, confirms that this mechanism has a statistically significant impact on weight loss in healthy overweight people.
For the full study, click here.
– by V. R. Trivedi et al. (2016)
Chitosan is a dietary fiber that acts by reducing absorption and thus as a means for controlling weight. Weight loss clinical trial outcomes, however, have contradictory results regarding its efficacy. The primary objective of the present study was to evaluate the efficacy and safety of chitosan from the fungal origin in the treatment of excess weight in the absence of dietary restrictions.
For the full study, click here.
– by European Food Safety Authority (EFSA)
European Food Safety Authority (EFSA) health claim: Contributes to weight reduction. Support in weight loss programs.
For a list of sources, click here.
– by European Food Safety Authority (EFSA)
European Food Safety Authority (EFSA) health claim: Contributes to bodyweight management. Contributes to lipid degradation. Helps maintain healthy body weight.
For a list of sources, click here.
– by European Food Safety Authority (EFSA)
European Food Safety Authority (EFSA) health claim: Contributes to bodyweight management. Contributes to lipid degradation.
For a list of sources, click here.
– by C. Di Lorenzo et al. (2014)
The objective of this review was to collect available data on the following: (i) adverse effects observed in humans from the intake of plant food supplements or botanical preparations; (ii) the misidentification of poisonous plants; and (iii) interactions between plant food supplements/botanicals and conventional drugs or nutrients.
PubMed/MEDLINE and Embase were searched from database inception to June 2014, using the terms ‘adverse effect/s’, ‘poisoning/s’, ‘plant food supplement/s’, ‘misidentification/s’ and ‘interaction/s’ in combination with the relevant plant name. All papers were critically evaluated according to the World Health Organization Guidelines for causality assessment.
Data were obtained for 66 plants that are common ingredients of plant food supplements; of the 492 papers selected, 402 (81.7%) dealt with adverse effects directly associated with the botanical and 89 (18.1%) concerned interactions with conventional drugs. Only one case was associated with misidentification. Adverse effects were reported for 39 of the 66 botanical substances searched. Of the total references, 86.6% were associated with 14 plants, including Glycine max/soybean (19.3%), Glycyrrhiza glabra/licorice (12.2%), Camellia sinensis/green tea ( 8.7%), and Ginkgo biloba/ginkgo (8.5%).
Considering the length of time examined and the number of plants included in the review, it is remarkable that: (i) the adverse effects due to botanical ingredients were relatively infrequent if assessed for causality; and (ii) the number of severe clinical reactions was very limited, but some fatal cases have been described. Data presented in this review were assessed for quality in order to make the results maximally useful for clinicians in identifying or excluding deleterious effects of botanicals.
For the full study, click here.
– by Gaurav Kumar et al. (2011)
Herbs and plants have been in use as a source of therapeutic compounds in traditional medicinal system since ancient time. Medicines plants play an important role in traditional health care systems as well as in international herbal and pharmaceutical markets. The medicinal value of these plants lies in some chemical substances that produce a definite physiological action on the human body. The most important of these bioactive constituents of plants are alkaloids, tannins, flavonoids and phenolic compounds. Z. officinale (Zingiberaceae) is an important plant with several ethnomedicinal and nutritional values therefore, used extensively worldwide as a spice, flavouring agent and herbal remedy. Traditionally, Z. officinale is used in Ayurveda, Siddha, Chinese, Arabian, Africans, Caribbean and many other medicinal systems to cure a variety of diseases viz, nausea, vomiting, asthma, cough, palpitaion, inflammation, dyspepsia, loss of appetite, constipation, indigestion and pain. In last few decades, Z. officinale is extensively studied for its medicinal properties by advanced scientific techniques and a variety of bioactive compounds have been isolated from the different parts of the plant and were analysed pharmacologically. The plant is reported for antimicrobial activity, anticancer activity, antioxidant activity, antidiabetic activity, nephroprotective activity, hepatoprotective activity, larvicidal activity, analgesic activity, anti-inflammatory activity and immunomodulatory activities. The present review is focused an overall outline of the morphology, distribution, phytochemistry and medicinal properties of Z. officinale and its future prospects for the further scientific investigation for the development of effective therapeutic compounds.
For the full study, click here.
– by European Medicines Agency (2012)
Ginger (Zingiberis rhizoma) consists of the whole or cut rhizome of Zingiber officinale Roscoe (Zingiberaceae), with the cork removed, either completely or from the wide, flat surfaces only [European Pharmacopoeia 2011]. Ginger plants have been extremely popular – for cooking as spice and to treat a host of ailments – throughout Asia, especially in India and China, for over 5000 years. The species Zingiber officinale originates from Southeast Asia. It is not known to occur wild [Teuscher 2006; Langner et al. 1998; Germer et al. 1997]. It is a perennial herb, up to 1.5 metre in height, with asymmetric flowers. Due to the long period of breeding in different continents, different types of the species have developed. The herbal substance ginger, that complies with the monograph of the European Pharmacopoeia, originates from the West Indian type (Jamaica-ginger) with the cork removed or from Indian types (Bengal-ginger, Cochin-ginger) peeled on the flattened sides only. Constituents: Volatile oil 1-4 % (minimum 15 ml/kg essential oil (anhydrous drug) according to the Ph. Eur.). More than 100 compounds are identified, most of them terpenoids mainly sesquiterpenoids (α-zingiberene, β-sesquiphellandrene, β-bisabolene, α-farnesene, ar-curcumene (zingiberol) and smaller amounts of monoterpenoids (camphene, β-phellandrene, cineole, geraniol, curcumene, citral, terpineol, borneol). The composition of the oil depends on the origin of the material [Afzal et al 2001; Ahmad et al. 2008; Ali et al. 2008; Chen & Ho 1988; Connell 1970; Erler et al. 1988; Lawrence 1984]. The pungent principles, the gingerols (4-7.5%) are a homologous series of phenols. The principal one of these is 6-gingerol. Gingerols with other chain-lengths, e.g., 8-gingerol and 10-gingerol, are present in smaller amounts. During drying and storage, gingerols are partly dehydrated to the corresponding shogaols which may undergo further reduction to form paradols, also present in stored ginger [Afzal et al. 2001; Bradley 1992; Connell 1970; Farthing & O’Neill 1990; Jolad et al. 2005; Kim et al. 2008; Steinegger & Stucki 1982]. Other constituents are starch, up to 50%, lipids 6-8%, proteins, and inorganic compounds [Awang 1992; ESCOP 2009]. The requirements of the US Pharmacopoeia for ginger are: gingerols and gingerdiones not less than 0.8%, volatile oil not less than 1.8 ml per 100 g, starch not less than 42% and shogaols not more than 0.18% [Bradley 1992; USP 2009].
For the full study, click here.
